Patoulias, D., & Kalogirou, M. Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. Termedia Publishing House.
Chicago Style (17th ed.) CitationPatoulias, Dimitrios, and Maria Kalogirou. Empagliflozin Promises to Bridge the Gap Between Non-alcoholic Fatty Liver Disease, Type 2 Diabetes, and Cardiovascular Disease. Termedia Publishing House.
MLA (9th ed.) CitationPatoulias, Dimitrios, and Maria Kalogirou. Empagliflozin Promises to Bridge the Gap Between Non-alcoholic Fatty Liver Disease, Type 2 Diabetes, and Cardiovascular Disease. Termedia Publishing House.
Warning: These citations may not always be 100% accurate.